May, 18 2017 12:36 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting

Results of Study of Lenvima (Lenvatinib) in Hepatocellular Carcinoma to Be Presented in Oral Session

TOKYO, May, 18 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima / Kisplyx, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, "eribulin"), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.

Detailed data regarding the results of a Phase III clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.

Major poster presentations will include a highlight of the results of a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and the results of a Phase I clinical trial of H3B-8800 in patients with advanced myeloid malignancies.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
April 20 2018 17:50 JST
 
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
April 19 2018 11:07 JST
 
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
April 13 2018 13:22 JST
 
Eisai Submits Supplemental New Drug Application to U.S. FDA
April 02 2018 12:44 JST
 
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
March 28 2018 18:33 JST
 
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
March 23 2018 14:41 JST
 
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
March 23 2018 13:40 JST
 
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
March 14 2018 11:16 JST
 
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
March 08 2018 13:33 JST
 
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
March 08 2018 12:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>